Executive Summary

Innocoll has received its first regulatory approval in the US, after its wholly-owned subsidiary, Innocoll Pharmaceuticals, gained 510k clearance for its advanced wound care product, CollaGUARD. The collagen-based dressing, which incorporates the firm's CollaRx membrane technology, can be used to manage superficial and deep wounds. The worldwide market for advanced wound care dressings is worth well over $1bn, the Ashburn, Virginia firm said, adding that because CollaGUARD can be manufactured using a "highly efficient and cost-effective process", it can compete "very favourably" against other collagen-based wound care products. CollaGUARD is already approved in Europe. Follow-up products currently in development include a silver-impregnated version of CollaGUARD for infected wounds or wounds at risk of infection, and DermaSIL, a collagen-synthetic foam composite dressing for deep and heavily exuding wounds.